Cargando…

P965: STEM-CELL MOBILIZATION WITH CYCLOPHOSPHAMIDE 4 G/M2 ALLOWS COLLECTION OF HIGH NUMBERS OF CD34+ CELLS AFTER DARA-VTD INDUCTION FOR MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales:	Perini, Tommaso, Liberatore, Carmine, Virginia, Girlando, Passeri, Cecilia, Ferla, Valeria, Iuliani, Ornella, Orsini, Alessia, Montanaro, Guido, Farina, Francesca, Nicola, Alessandro DI, Marktel, Sarah, Pulini, Stefano, Santarone, Stella, Accorsi, Patrizia, Ciceri, Fabio, Ianni, Mauro DI, Marcatti, Magda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431584/ http://dx.doi.org/10.1097/01.HS9.0000970764.05968.ba

Ejemplares similares

Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma
por: Liberatore, Carmine, et al.
Publicado: (2023)

P24 HIGH-DOSE CYCLOPHOSPHAMIDE 4 GR/M2 AND STEM-CELL COLLECTION AFTER DARATUMUMAB-BASED QUADRUPLET INDUCTION IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS: A SINGLE-CENTER EXPERIENCE
por: Liberatore, C., et al.
Publicado: (2023)

Daratumumab‐based induction and autologous transplantation in concomitant multiple myeloma and chronic myeloid leukemia
por: Liberatore, Carmine, et al.
Publicado: (2023)

Dara Ó Briain's visit to CERN
por: Rao, Achintya
Publicado: (2017)

Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching
por: Moreau, Philippe, et al.
Publicado: (2020)

Pide y se te dará : aprende a manifestar tus deseos /
por: Hicks, Esther
Publicado: (2005)

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
por: Fouquet, Guillemette, et al.
Publicado: (2014)

Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
por: Lee, Yoo Jin, et al.
Publicado: (2019)

P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN
por: Del Fabro, V., et al.
Publicado: (2023)

VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience
por: Ghandili, Susanne, et al.
Publicado: (2022)

Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation
por: Liberatore, Carmine, et al.
Publicado: (2023)

Cristina dará hoy su discurso en la OIT
Publicado: (2009)

Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosis
por: Srkalovic, Gordan, et al.
Publicado: (2005)

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy
por: Ferla, Valeria, et al.
Publicado: (2022)

Shrimp miR-965 transfers tumoricidal mitochondria
por: Kim, Hyueyun, et al.
Publicado: (2022)

PB2575: HIGH INCIDENCE OF RESPIRATORY TRACT INFECTIONS FOLLOWING COVID-19 WAVES IN PATIENTS WITH PLASMA CELL DYSCRASIAS
por: Farina, Francesca, et al.
Publicado: (2023)

965. Applying Clinical Prediction Tools to Patients with Lassa Fever
por: Chiosi, John, et al.
Publicado: (2018)

Case Report: Invasive Fungal Infection and Daratumumab: A Case Series and Review of Literature
por: Farina, Francesca, et al.
Publicado: (2022)

Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible
por: Sonneveld, Pieter, et al.
Publicado: (2020)

Methodology for the Development of Augmented Reality Applications: MeDARA. Drone Flight Case Study
por: Zamora-Antuñano, Marco Antonio, et al.
Publicado: (2022)

965. Advanced Practice Providers in Infectious Disease: Educational Needs and Opportunities
por: Yoke, Leah H, et al.
Publicado: (2021)

Psychometric Characteristics of Different Versions of Vocal Tract Discomfort (VTD) Scale: A Systematic Review
por: Aghaei, Fateme, et al.
Publicado: (2022)

The Influence of Lunar Phases on Complications in Cataract Surgery: An Analysis of 16,965 Patients
por: Faschinger, Eva-Maria, et al.
Publicado: (2017)

965. The Efficacy of Oral Β-lactam Antibiotics as Step-down Therapy for Acute Pyelonephritis
por: Hobbs, Athena L V, et al.
Publicado: (2019)

965. Projecting the Potential Clinical and Economic Impact of HIV Prevention Resource Reallocation in Tennessee
por: Borre, Ethan D, et al.
Publicado: (2023)

Homocysteine and education but not lipoprotein (a) predict estimated 10-year risk of cardiovascular disease in blood donors: a community based cross-sectional study
por: Vadini, Francesco, et al.
Publicado: (2019)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
por: Zhou, Xiang, et al.
Publicado: (2020)

miR-965 controls cell proliferation and migration during tissue morphogenesis in the Drosophila abdomen
por: Verma, Pushpa, et al.
Publicado: (2015)

Meta-Analysis Identifies Gene-by-Environment Interactions as Demonstrated in a Study of 4,965 Mice
por: Kang, Eun Yong, et al.
Publicado: (2014)

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma
por: Nadiminti, Kalyan, et al.
Publicado: (2017)

DARA: a web server for rapid search of structural neighbours using solution small angle X-ray scattering data
por: Kikhney, Alexey G., et al.
Publicado: (2016)

S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS
por: Bahlis, Nizar J, et al.
Publicado: (2023)

Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide
por: Greco, Raffaella, et al.
Publicado: (2019)

P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI
por: Mateos, M, et al.
Publicado: (2023)

NOTCH and Graft-Versus-Host Disease
por: Di Ianni, Mauro, et al.
Publicado: (2018)

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
por: Terragna, Carolina, et al.
Publicado: (2015)

Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study
por: Byun, Ja Min, et al.
Publicado: (2023)

Fatigue as Mediator Factor in PTSD-Symptoms after Allogeneic Hematopoietic Stem Cell Transplantation
por: Di Francesco, Giulia, et al.
Publicado: (2023)

Incidence of fractures among children and adolescents in rural and urban communities - analysis based on 9,965 fracture events
por: Hedström, Erik M, et al.
Publicado: (2014)

HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients
por: Braicu, Elena Ioana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ifrachv67j3391v19u5ftpcifl